Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 58 % of short-term debt in 2025; threshold 65 %.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
In Utero from Antwerpen, company number BE0776895170, closed financial year 2025 with a result of € 7,685 after tax. For that financial year In Utero recorded a gross margin of € 97,314 and equity of € -63,946. Compared with financial year 2024, the result moved from € 5,432 to € 7,685. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 30, 2026.
€ -63,946
▲ € 7,685 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 7,685
▲ 41% vs 2024
Profit after tax over the fiscal year.
€ 16,956
▲ 24% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -93,946.
People and assets in 2025
€ 13,490
▼ 13% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 1.4 million
▼ 7% vs 2024
€ 102,371 is repaid this year. At this pace the long-term loan is gone in ≈ 14 years.
€ 5,906
▲ 7% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -70,209 | € 78,381 | € 96,290 | € 97,314 | ▲ 1% |
| Profit after taxes | € -97,822 | € -9,241 | € 5,432 | € 7,685 | ▲ 41% |
| Equity | € -67,822 | € -77,063 | € -71,631 | € -63,946 | ▲ € 7,685 |
| Total debts | € 1,561,006 | € 1,727,966 | € 1,638,340 | € 1,546,174 | ▼ 6% |
| Cash | € 25,584 | € 9,499 | € 13,693 | € 16,956 | ▲ 24% |
| Land & buildings | € 1,433,162 | € 1,487,755 | € 1,419,404 | € 1,351,054 | ▼ 5% |
| Retained profit | € -97,822 | € -107,063 | € -101,631 | € -93,946 | ▲ € 7,685 |
| Bank debt | € 1,440,068 | € 1,679,565 | € 1,543,762 | € 1,436,017 | ▼ 7% |
| Balance sheet total | € 1,493,184 | € 1,650,902 | € 1,566,709 | € 1,482,228 | ▼ 5% |
Key figures of In Utero, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to In Utero?
What happened at In Utero in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 7,685 (▲ 41% vs 2024). Source: NBB ↗
- New establishment in Antwerpen. KBO
- Dr. Tinneke De Souter - gynaecologie BV became a director. NBB
- Dr. Laura Werquin BV became a director. NBB
- Dr. M. Ysebaert BV became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 97,822 loss in 2022 to € 7,685 profit in 2025.
Best year ever: 2025, with € 7,685 profit.
A new publication or filing at In Utero? We notify you, reason included.
Follow In UteroDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of DR. TINNEKE DE SOUTER - GYNAECOLOGIE, Dr. M. Ysebaert, DR. LAURA WERQUIN comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
In UteroBehind In Utero are Dr. Tinneke De Souter - gynaecologie BV, Dr. Laura Werquin BV and Dr. M. Ysebaert BV. The shares are held by DR. TINNEKE DE SOUTER - GYNAECOLOGIE (33.3%), Dr. M. Ysebaert (33.3%) and DR. LAURA WERQUIN (33.3%).
Directors
According to the 2025 annual accounts
Dr. Tinneke De Souter - gynaecologie BV
Director · represented by Tinneke De Souter
since 2021
Director · represented by Werquin Laura
since 2021
Director · represented by Ysebaert Marijke
since 2021
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Hessenstraatje 16 box 1L
2000 Antwerpen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0776.895.170
- VAT number
- BE 0776.895.170
- Registered office
- Hessenstraatje 16 bus 1L, 2000 Antwerpen
- Names & denominations
- In Utero
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 8 November 2021
- Peppol
- Not registered